Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Market Reaction Muted

Amylyx Pharmaceuticals Inc released its second-quarter 2025 financial results, posting a net loss of $41.4 million, or $0.46 per share, aligning closely with analyst expectations of a $0.454 loss per share. Revenue for the quarter was reported at $0, also matching estimates. The company’s financial performance reflects its continued investment in clinical-stage programs, with no commercial revenue currently generated.

Market Reaction
Following the earnings release, pre-market trading showed a slight decline of approximately 2.3%, suggesting a neutral to slightly negative reaction from investors. Over the past month, the stock has gained around 13%, indicating broader optimism about the company’s pipeline, but the immediate post-earnings movement reflects cautious sentiment.

Key Financial Highlights

• R&D Expenses: Increased to $27.2 million (up from $23.3 million in Q2 2024), driven by clinical development of avexitide and AMX0035.
• SG&A Expenses: Decreased to $15.6 million (down from $21.6 million in Q2 2024), reflecting reduced payroll and consulting costs.
• Cash Position: Ended the quarter with $180.8 million in cash and equivalents, with an expected runway through the end of 2026.

Pipeline and Clinical Updates
Amylyx provided updates on several key programs:

• Avexitide (PBH): The pivotal Phase 3 LUCIDITY trial is on track for completion in 2025, with topline data expected in H1 2026. Recent Phase 2b data showed a 64% reduction in hypoglycemic events.
• AMX0035 (Wolfram syndrome & PSP): Long-term Week 48 data from the HELIOS trial demonstrated sustained improvements in pancreatic function. An unblinded analysis of the Phase 2b ORION trial in PSP is expected in Q3 2025.
• AMX0114 (ALS): Received FDA Fast Track designation, with early Phase 1 LUMINA trial data anticipated later this year.

Outlook vs. Analyst Estimates
While Amylyx did not provide explicit forward revenue or EPS guidance, analysts project a full-year 2025 EPS loss of $1.87 and no revenue. For Q3 2025, estimates suggest a loss of $0.459 per share. The company’s focus remains on clinical milestones rather than near-term profitability, which aligns with its development-stage status.

Conclusion
Amylyx’s Q2 results were largely in line with expectations, reinforcing its position as a clinical-stage biotech with multiple catalysts ahead. The muted market reaction suggests investors are waiting for more concrete data readouts before making significant moves.

For more detailed earnings estimates and historical performance, visit Amylyx Pharmaceuticals’ earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research before making decisions.